Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Irl Press At Oxford University Press Country of Publication: England NLM ID: 8008055 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1460-2180 (Electronic) Linking ISSN: 01433334 NLM ISO Abbreviation: Carcinogenesis Subsets: MEDLINE
    • بيانات النشر:
      Publication: Oxford : Irl Press At Oxford University Press
      Original Publication: [New York, IRL Press]
    • الموضوع:
      Genetic Association Studies* ; Genetic Predisposition to Disease*; Prostatic Neoplasms/*genetics ; Wnt Signaling Pathway/*genetics; Aged ; Casein Kinase II/genetics ; Genotype ; Humans ; Male ; Middle Aged ; Neoplasm Invasiveness/genetics ; Neoplasm Proteins/genetics ; Neoplasm Staging ; Polymorphism, Single Nucleotide ; Prostatic Neoplasms/classification ; Prostatic Neoplasms/pathology ; Risk Factors
    • نبذة مختصرة :
      Little is known about the genetic predictors of prostate cancer aggressiveness and reclassification in men with localized prostate cancer undergoing active surveillance. The Wnt signaling pathway is important for prostate cancer development and progression. Identifying genetic variants associated with prostate cancer aggressiveness and reclassification may have a potential role in the management of localized patients. In this study, we used a three-phase design. In phases I and II prostate cancer patient cohort, 578 single nucleotide polymorphisms (SNPs) from 45 genes of the Wnt signaling pathway were analyzed in 1762 localized prostate cancer patients. Twelve SNPs from four regions were significantly associated with aggressive disease, among which, three linked SNPs in CSNK1A1 at 5q32 (represented by rs752822) may differentiate GS 4+3 from GS 3+4 patients (OR = 1.44, 95% CI = 1.12-1.87, P = 4.76×10(-3)). In phase III active surveillance (AS) cohort, genotyping of rs752822 (candidate from phases I and II) and previously identified rs2735839 were determined in 494 GS ≤7 patients. We found a significant association between rs2735839 and prostate cancer reclassification in the AS cohort (AG + AA versus GG, HR = 1.59, 95% CI = 1.11-2.28, P = 0.012) and a suggestive association of rs752822. Jointly, rs752822 and rs2735839 showed good potentials in risk-stratifying GS 7 patients and predicting disease reclassification (OR = 2.71, 95% CI = 1.62-4.51, P = 1×10(-4) in phase II; HR = 1.89, 95% CI = 1.13-3.18, P = 0.016 in phase III). In summary, rs752822 and rs2735839 may assist in risk-stratifying GS 7 patients and predict prostate cancer reclassification. The significant associations were independent from GS, T stage and PSA levels at baseline.
      (© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
    • References:
      Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24. (PMID: 12781368)
      Oncogene. 2006 Jun 8;25(24):3436-44. (PMID: 16474850)
      Clin Cancer Res. 2014 Oct 1;20(19):5133-9. (PMID: 25274378)
      J Surg Oncol. 2014 Jun;109(8):830-5. (PMID: 24610744)
      Nat Rev Urol. 2014 Jan;11(1):18-31. (PMID: 24296704)
      Eur Urol. 2012 Dec;62(6):976-83. (PMID: 22698574)
      Prostate. 2009 Aug 1;69(11):1195-205. (PMID: 19434657)
      BJU Int. 2013 Sep;112(5):666-73. (PMID: 23320731)
      Eur Urol. 2016 Feb;69(2):223-8. (PMID: 26411806)
      Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210)
      Eur Urol. 2013 Dec;64(6):876-92. (PMID: 23787356)
      Dev Cell. 2009 Jul;17(1):9-26. (PMID: 19619488)
      Cold Spring Harb Perspect Biol. 2013 Jan 01;5(1):a007898. (PMID: 23169527)
      Sci Transl Med. 2010 Dec 15;2(62):62ra92. (PMID: 21160077)
      Nat Genet. 2008 Mar;40(3):316-21. (PMID: 18264097)
      Nat Commun. 2015 May 05;6:6889. (PMID: 25939597)
      Oncogene. 2003 Aug 28;22(36):5602-13. (PMID: 12944908)
      Cancer Lett. 2006 Jun 8;237(1):22-32. (PMID: 16023783)
      Cancer Res. 2009 Apr 15;69(8):3332-8. (PMID: 19351848)
      J Clin Oncol. 2011 Sep 20;29(27):3669-76. (PMID: 21825257)
      PLoS One. 2011 Feb 24;6(2):e17142. (PMID: 21390317)
      Nat Genet. 2014 Oct;46(10):1103-9. (PMID: 25217961)
      BJU Int. 2016 Jul;118(1):68-76. (PMID: 26059275)
      Nat Rev Urol. 2012 Aug;9(8):418-28. (PMID: 22710668)
    • Grant Information:
      P50 CA140388 United States CA NCI NIH HHS
    • الرقم المعرف:
      0 (Neoplasm Proteins)
      EC 2.7.11.1 (CSNK2A1 protein, human)
      EC 2.7.11.1 (Casein Kinase II)
    • الموضوع:
      Date Created: 20160813 Date Completed: 20170519 Latest Revision: 20210103
    • الموضوع:
      20221213
    • الرقم المعرف:
      PMC5035398
    • الرقم المعرف:
      10.1093/carcin/bgw082
    • الرقم المعرف:
      27515962